Inhibrx Inc (INBX)
34.31
-0.39
(-1.12%)
USD |
NASDAQ |
May 10, 16:00
34.31
0.00 (0.00%)
After-Hours: 18:14
Inhibrx Enterprise Value: 1.574B for May 9, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 09, 2024 | 1.574B |
| May 08, 2024 | 1.561B |
| May 07, 2024 | 1.559B |
| May 06, 2024 | 1.555B |
| May 03, 2024 | 1.547B |
| May 02, 2024 | 1.541B |
| May 01, 2024 | 1.555B |
| April 30, 2024 | 1.542B |
| April 29, 2024 | 1.548B |
| April 26, 2024 | 1.543B |
| April 25, 2024 | 1.545B |
| April 24, 2024 | 1.558B |
| April 23, 2024 | 1.547B |
| April 22, 2024 | 1.545B |
| April 19, 2024 | 1.556B |
| April 18, 2024 | 1.562B |
| April 17, 2024 | 1.569B |
| April 16, 2024 | 1.569B |
| April 15, 2024 | 1.575B |
| April 12, 2024 | 1.587B |
| April 11, 2024 | 1.589B |
| April 10, 2024 | 1.586B |
| April 09, 2024 | 1.584B |
| April 08, 2024 | 1.574B |
| April 05, 2024 | 1.586B |
| Date | Value |
|---|---|
| April 04, 2024 | 1.571B |
| April 03, 2024 | 1.592B |
| April 02, 2024 | 1.581B |
| April 01, 2024 | 1.582B |
| March 28, 2024 | 1.586B |
| March 27, 2024 | 1.595B |
| March 26, 2024 | 1.591B |
| March 25, 2024 | 1.585B |
| March 22, 2024 | 1.583B |
| March 21, 2024 | 1.586B |
| March 20, 2024 | 1.588B |
| March 19, 2024 | 1.587B |
| March 18, 2024 | 1.585B |
| March 15, 2024 | 1.588B |
| March 14, 2024 | 1.587B |
| March 13, 2024 | 1.604B |
| March 12, 2024 | 1.599B |
| March 11, 2024 | 1.595B |
| March 08, 2024 | 1.613B |
| March 07, 2024 | 1.624B |
| March 06, 2024 | 1.621B |
| March 05, 2024 | 1.615B |
| March 04, 2024 | 1.618B |
| March 01, 2024 | 1.656B |
| February 29, 2024 | 1.665B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
298.27M
Minimum
Jun 14 2022
1.804B
Maximum
Feb 27 2024
1.009B
Average
959.87M
Median
Enterprise Value Benchmarks
| Axonics Inc | 3.107B |
| NovaBay Pharmaceuticals Inc | 2.645M |
| Palatin Technologies Inc | 28.44M |
| iBio Inc | 16.42M |
| Theriva Biologics Inc | -13.29M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -93.60M |
| Revenue (Quarterly) | 1.634M |
| Total Expenses (Quarterly) | 89.92M |
| EPS Diluted (Quarterly) | -1.82 |
| Profit Margin (Quarterly) | -5.73K% |
| Earnings Yield | -14.92% |
| Normalized Earnings Yield | -14.92 |